Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

<ul><li>Poonawalla has rented out a mansion in Mayfair, London from Polish billionaire Dominika Kulczyk.</li><li>His new neighbours would be billionaires from around the world – a Chinese heiress, businessman John Caudwell who owns the phone retail company Phones 4u.</li><li>But there’s more to Mayfair’s history.</li></ul><keyword id="383467" type="PERSON" weightage="20" keywordseo="Adar-Poonawalla">Adar Poonawalla</keyword> is a busy man, after all he’s the man behind Serum Institute of India (SII) -- the largest vaccine manufacturer in the world that has most recently made the Oxford-Astrazeneca COVID-19 vaccine. Poonawalla, who belongs to one of India’s richest families, has a new address. Poonawalla has reportedly <a href="https://www.bloombergquint.com/business/ceo-rents-london-mansion-for-69-000-a-week-in-mayfair-record">rented out</a> a mansion in Mayfair, one of the most expensive residential areas in the world. Mayfair is in the city of Westminster, which falls within the greater London area. Poonawalla is shelling out $69,000 or just over ₹50 lakh as rent per week for his new house. Poonawalla is renting the property from Polish billionaire Dominika Kulczyk. The home is one of the biggest in the district and spreads across 25,000 square feet – which is <a href="https://www.ndtv.com/india-news/adar-poonawalla-rents-uk-mansion-for-69-000-a-week-report-2398321">reportedly </a>as much as 24 average homes, put together, in the UK. Poonawalla, who is an alumnus of the University of Westminster, has often referred to London as his second home. The billionaire’s rental in London comes at a time when the city’s real estate is recovering fast after the COVID-19 induced lull. According to real estate consulting firm Knight Frank, the total number of prospective buyers who are looking at over £10 million properties had doubled by January 2021, as compared to the year before. His new neighbours would be billionaires from around the world – a <a href="https://www.dailymail.co.uk/femail/article-9290657/Chinese-heiress-24-rents-five-bedroom-Mayfair-townhouse-record-breaking-130-000-MONTH.html">Chinese</a> heiress, businessman John Caudwell, who owns the phone retail company Phones 4u, among others. <cmsannotation type="cmsannotation" annotationid="Home to history" comment="subhead" text="Home to history">Home to history</cmsannotation> Poonawalla’s new Mayfair home also houses historic significance. The area is home to British royalty, dukes and duchesses. In fact, according to reports, of the 227 houses built in the area, hundreds of years ago, 117 belonged to those who had titles. The area also has some of the most <a href="https://www.thesun.co.uk/news/12391019/britains-most-expensive-homes-250m-mayfair-mega-mansion/">expensive homes</a> in Britain. Mayfair also houses the first bachelor pad of Britain’s former Prime Minister Winston Churchill. It was there that Churchill laid the foundation of his political career and was also the place where he wrote his first book Ian Hamilton’s March. So, of course, Mayfair properties don’t come cheap. As per Knight Frank, houses in Mayfair was sold for an average of £7.3 million in 2020. And for Poonawalla this isn’t the first historic or major real estate splurge. Poonawalla, who already owns some of the biggest and luxurious homes in India, had also <a href="https://qz.com/india/501268/record-breaking-sale-a-billionaire-has-bought-the-former-us-consulate-in-mumbai-for-113-million/">made news</a> in 2015 when he bought out the Mumbai mansion, which was once the address for the US consulate. He had paid a whopping $113 million for the home. SEE ALSO: <a href="https://www.businessinsider.in/business/startups/news/khatabook-acquires-saas-business-management-app-biz-analyst-for-10-million/articleshow/81683288.cms">Khatabook acquires SaaS business management app Biz Analyst for $10 million</a>

India’s vaccine king Adar Poonawalla will pay $69,000 a week to live on the same neighbourhood as Winston Churchill once did

<ul class="summary-list"><li><keyword id="383467" type="PERSON" weightage="60" keywordseo="Adar-Poonawalla">Adar Poonawalla</keyword>, the leader of a major <keyword id="24209" type="PERSON" weightage="60" keywordseo="vaccine">vaccine</keyword> manufacturer, said he fled <keyword id="3658" type="COUNTRY" weightage="60" keywordseo="India">India</keyword> due to threats.</li><li>Poonawalla leads the Serum Institute, the world's largest vaccine manufacturer.</li><li>The COVID-19 situation in India is so dire that Poonawalla said people have been hurling threats at him, accusing him of delaying vaccines on purpose.</li></ul>The CEO of the Serum Institute, a vaccine manufacturer in India, said he fled the country because of incessant threats against him. In an <a href="https://www.thetimes.co.uk/article/adar-poonawalla-aggression-over-covid-vaccines-is-overwhelming-everyone-expects-to-get-theirs-first-bfqbgcm96?utm_medium=Social&amp;utm_source=Twitter#Echobox=16198538343834">interview</a> with the Times of London, Adar Poonawalla said he went to England to escape threats from people claiming he's holding up vaccines."'Threats' is an understatement," Poonawalla said. "The level of expectation and aggression is really unprecedented.""It's overwhelming. Everyone feels they should get the vaccine. They can't understand why anyone else should get it before them," he added. "They are saying if you don't give us the vaccine it's not going to be good. It's not foul language. It's the tone. It's the implication of what they might do if I don't comply."The Serum Institute is the world's largest vaccine manufacturer, <a href="https://www.bbc.com/news/world-asia-india-55748124#:~:text=What%20about%20Covishield%3F,60%20million%20doses%20a%20month.">producing more than 60 million doses</a> of the AstraZeneca and Oxford vaccine every month. At the time of his interview, Poonawalla said he'd stay in England for "an extended time, because I don't want to go back to that situation.""Everything falls on my shoulders, but I can't do it alone," he added. Hours after the interview was published, Poonawalla backtracked and wrote on Twitter that he'd return to India "in a few days."The news of his departure from India comes as the country experiences deep surges in positive COVID-19 cases.The nation reported a record high of <a href="https://www.businessinsider.com/india-first-country-to-record-400000-single-day-coronavirus-cases-2021-5">401,993 new cases of COVID-19</a> on Saturday. No other country has breached 400,000 daily cases.Crematoriums across India are overwhelmed with bodies. Patients are <a href="https://www.cnn.com/world/live-news/coronavirus-pandemic-vaccine-updates-05-01-21/h_3485a084f1fa06acfc2aa0d1cd2046fd?tab=India">dying</a> as hospitals run out of oxygen. The country had reported more than 300,000 new cases each day for nine consecutive days before hitting the 400,000 mark.India also reported more than 3,500 deaths on Saturday - the fourth day in a row that death counts have surpassed 3,000. Those numbers are likely an undercount. A <a href="https://www.nytimes.com/2021/04/24/world/asia/india-coronavirus-deaths.html" target="_blank" rel="noopener">New York Times</a> investigation published this week found "mounting evidence" that suggested fatalities are being "overlooked or downplayed" by the government. The situation has gotten so bad that people have surrounded his company multiple times and called him a "profiteer" of the COVID-19 vaccines."I don't think even God could have forecast it was going to get this bad," Poonawalla said in the interview.Insider's Morgan McFall-Johnsen contributed to this report.

The leader of one of the world's biggest vaccine manufacturers said he fled India because of menacing threats

<keyword id="242973" type="General" weightage="20" keywordseo="serum-institute" source="Orion">Serum Institute</keyword> of India (SII) plans to launch a COVID vaccine for children in the next six months, the company's CEO <keyword id="383467" type="General" weightage="20" keywordseo="adar-poonawalla" source="Orion">Adar Poonawalla</keyword> said on Tuesday. Participating in an industry conference, Poonawalla said the vaccine '<keyword id="10678894" type="General" weightage="20" keywordseo="covovax" source="Orion">Covovax</keyword>' is under trial and would offer protection to children all the way down till three years. Currently, <keyword id="9617748" type="General" weightage="20" keywordseo="covishield" source="Orion">Covishield</keyword> and other COVID vaccines are approved for people above the age of 18 years. "We haven't seen a lot of severe disease in children. Fortunately, the panic is not there for children. However, we will be launching a vaccine in six months for children, hopefully down to the age of three," Poonawalla said. He noted that already there are two companies in India who are licensed and their vaccines will be available soon. "I think yes, you should take and get your children vaccinated. There is no harm, these vaccines have been proven to be safe and efficacious and all of that. If you feel you want to get your children vaccinated by all means wait for government announcements on that and you go ahead with that. "Our vaccine Covovax will be launched for children in six months," Poonawalla said, adding that Covovax is under trial and has shown excellent data all the way down to the age group of three years. Further, Poonawalla said there was enough data to show that the vaccines will work and protect the children against the infectious disease. He pointed out that so far nothing can be said about the <keyword id="1609796" type="General" weightage="50" keywordseo="omicron" source="Orion">Omicron</keyword> variant as to how it would impact the children. "I don't know what will happen with Omicron but so far the children have not been affected very badly with this (COVID) virus. I think their body, cells and their lungs recover better," he said. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/india/news/delhi-reports-four-new-cases-of-omicron-covid-19-variant-says-health-minister/articleshow/88274332.cms">Delhi reports four new cases of Omicron COVID-19 variant, says Health Minister</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/international/news/china-reports-first-case-of-omicron-variant-in-the-port-city-of-tianjin-say-media-reports/articleshow/88273319.cms">China reports first case of Omicron variant in the port city of Tianjin, say media reports</a>

Serum Institute to roll out COVID-19 vaccine for children in six months, says CEO Adar Poonawalla

<keyword id="95879" type="General" weightage="50" keywordseo="serum-institute-of-india" source="Orion">Serum Institute of India</keyword>'s Chief Executive Officer <keyword id="383467" type="General" weightage="50" keywordseo="adar-poonawalla" source="Orion">Adar Poonawalla</keyword> has said their <keyword id="10678894" type="General" weightage="100" keywordseo="covovax" source="Orion">Covovax</keyword> vaccine will get approval as a booster against COVID-19 in the next 10 to 15 days. The vaccine works very well against the <keyword id="1609796" type="General" weightage="50" keywordseo="omicron" source="Orion">Omicron</keyword> variant of coronavirus, <keyword id="25607" type="General" weightage="80" keywordseo="poonawalla" source="Orion">Poonawalla</keyword> told reporters on the sidelines of an event at the Bharti Vidyapeeth University here on Sunday. Asked about states and districts not getting Covishield vaccine, he said there is ample stock with the Union government for supply. "Covovax will be approved as a booster in the next 10-15 days. It is actually the best booster because it works very well against Omicron, more than Covishield," he said. Poonawalla said everyone was looking at India, not just in terms of healthcare but because the country managed to take care of a huge and diverse population and also helped 70 to 80 nations during the COVID-19 pandemic. "This was all possible because of the leadership of our central government, our state governments, healthcare workers, manufacturers, all of whom worked together with one common goal," he said. On the occasion, Poonawalla was conferred with the first Dr Pantangrao Kadam Memorial Award at the hands of Nationalist Congress Party (NCP) chief Sharad Pawar and Maharashtra Deputy Chief Minister Devendra Fadnavis. The event was held to mark the birth anniversary of Kadam, the late minister and education baron from western Maharashtra. Appealing to students who wished to pursue education abroad, Poonawalla said there was no place like India to fulfil dreams due to the presence of institutions like Bharti Vidyapeeth and others. "Even if you have to go abroad, come back as soon as possible," he said. SEE ALSO: <a href="https://www.businessinsider.in/thelife/personalities/news/gautam-adani-aap-ki-adalat-interview-dhirubhai-ambani-is-my-role-model-mukesh-ambani-a-very-good-friend/articleshow/96828407.cms">Dhirubhai Ambani is my role model and Mukesh Ambani a very good friend, says Gautam Adani</a> <a href="https://www.businessinsider.in/tech/news/online-mental-health-company-uses-chatgpt-to-help-respond-to-users-in-experiment-raising-ethical-concerns-around-healthcare-and-ai-technology/articleshow/96821802.cms">Online mental health company uses ChatGPT to help respond to users in experiment — raising ethical concerns around healthcare and AI technology</a>

Covovax vaccine to get approval as a booster in 10-15 days: Adar Poonawalla

<ul><li>The 74-year old is the 12th richest person in India with a networth of $9.5 billion. </li><li>According to Forbes, he multiplied his net worth nearly five times in a decade. But his company Serum Institute of India (SII) is known for its affordable vaccines. </li><li>The affordable vaccine strategy has struck the right cord of the company as its annual revenues are at ₹59 billion ($840 million).</li></ul>The story of <keyword id="29334" type="PERSON" weightage="20" keywordseo="Cyrus-Poonawalla">Cyrus Poonawalla</keyword> and how he became a billionaire cuts through luxury cars, horses and vaccines. The 74-year old <a href="https://www.forbes.com/profile/cyrus-poonawalla/">is the 12th richest person in India</a> with a networth of $9.5 billion. According to Forbes, he multiplied his net worth nearly five times in a decade. But his company Serum Institute of India (SII) is known for its affordable vaccines. He founded the Serum Institute of India in 1966, with a capital of $12,000. His idea was to develop vaccines by extracting serum from horses. SII became the world’s largest vaccine maker by of doses produced and sells 1.5 billion doses globally. <div type="Slideshow" msid="72139267" hostid="261" title="Cyrus Poonawalla, India’s vaccine king, multiplied his wealth nearly 5 times in a decade" firstImageMsid="72139269" slideCount="4"></div>

Cyrus Poonawalla, India’s vaccine king, multiplied his wealth nearly 5 times in a decade

Vaccine maker Serum Institute of India's <keyword id="9625152" type="UNKNOWN" weightage="20" keywordseo="ceo-adar-poonawalla">CEO Adar Poonawalla</keyword> on Thursday said the Oxford COVID-19 vaccine should be available for <keyword id="893440" type="PERSON" weightage="20" keywordseo="healthcare-workers">healthcare workers</keyword> and <keyword id="56756" type="PERSON" weightage="20" keywordseo="Elderly-people">elderly people</keyword> by around February 2021 and by April for the general public, and will be priced at a maximum of Rs 1,000 for two necessary doses for the public, depending on the final trial results and regulatory approvals. Probably by 2024, every Indian will get vaccinated, he said at the Hindustan Times Leadership Summit (HTLS), 2020. "It will probably take two or three years for every Indian to get inoculated, not just because of the supply constraints but because you need the budget, the vaccine, logistics, infrastructure and then, people should be willing to take the vaccine. So these are the factors that lead up to being able to vaccinate 80-90 per cent of the population. "It will be 2024 for everybody, if willing to take a two-dose vaccine, to be vaccinated," Poonawalla said. Asked at what price the public will get it, he said it will be around USD 5-6 per dose with an MRP of around Rs 1,000 for the two necessary doses. "The government of India will be getting it at a far cheaper price at around USD 3-4, because it will be buying in a large volume and get access to the price that is similar to what COVAX has got. We are still pricing it far cheaper and more affordable than other vaccines we have in the market today," Poonawalla said. Asked about the efficacy of the vaccine, he said the Oxford-Astrazeneca vaccine is so far proving to work very well even in elderly people, which was a concern earlier. "It has induced a good T-cell response, which is an indicator for your long-term immunity and antibody response but then again, time will only tell if these vaccines are going to protect you in the long term. Nobody can answer that for any of the vaccines today," Poonawalla said. Responding to a question on the safety aspect, he said there has been no major complaints, reactions or adverse events, adding, "We would need to wait and see. The efficacy and immunogenicity results from the Indian trials will come out in about a month-and-a half." Asked when the SII will apply for an emergency authorisation, Poonawalla said as soon as the UK authorities and the European Medicines Evaluation Agency (EMEA) approve it for emergency use, it will apply to the drug controller for emergency use authorisation in India. "But that will be for a limited use for frontline workers, healthcare workers and elderly people," he added. Children would have to wait a little longer till the safety data is out, but the good news is that COVID-19 is not so bad and serious for them, Poonawalla said. "Unlike measles pneumonia, which is deadly, this disease is seeming to be less of a nuisance for children but then, they can be carriers and can give the infection to others. "We want to vaccinate the elderly people and others who are the most vulnerable first. Once we have enough safety data to go in on children, we can recommend it for children too," he said. Poonawalla said the Oxford vaccine is affordable, safe and stored at a temperature of two to eight degrees Celsius, which is an ideal temperature for it to be stored in the cold storages of India. He said the SII plans to make about 10 crore doses per month from February. As regards how many doses would be provided to India, Poonawalla said talks are still going on and no agreement has been arrived at in this regard. "India wants around 400 million doses by July. I do not know if it will take all from <keyword id="9265406" type="COMPANY" weightage="20" keywordseo="the-serum-institute">the Serum Institute</keyword>. We are gearing up to offer that kind of volume to India and still have a few 100 million to offer to COVAX by July and August. No agreement so far," he said. Poonawala said the SII is not entering into any agreement with other countries at this moment as India is its priority. "We have not signed and committed anything else beyond Bangladesh at the moment. We really do not want to partner right now with many countries because we will not have enough stocks to deliver. "We want to handle India as a priority first and manage Africa at the same time and then help out other countries," he said. Poonawalla said 30-40 crore doses of the Oxford vaccine will be available by the first quarter of 2021. In another session of the summit, AIIMS Director Dr Randeep Guleria said there is some talk going on between Pfizer and the Indian government but not much with Moderna. "It is going to be a huge challenge as far as the Pfizer vaccine is concerned, considering that it needs a cold chain of minus 70 degrees Celsius," he said and pinned hoped on the vaccines that are at various stages of trial in India. On the availability of a COVID-19 vaccine, Guleria said the percentage of population to be inoculated will depend on the number of vaccines getting the regulatory approvals and the number of shots they are producing. He further said the <keyword id="1754604" type="PERSON" weightage="20" keywordseo="coronavirus">coronavirus</keyword> goes into the lungs without making a person symptomatic. "We have individuals who are asymptomatic and you can see patches in their lungs at CT scans directly. It really bypasses a person's defence mechanism, which means that you not only have the virus in your nose or throat, but it has gone right into your lungs. A virus which can do that is something we have to be wary of," Guleria said. PLB/UZM RC

COVID-19 vaccine will be priced at ₹1,000 and would be available by February for healthcare workers and elderly people, says Serum CEO Adar Poonawalla

<keyword id="383467" type="PERSON" weightage="20" keywordseo="Adar-Poonawalla">Adar Poonawalla</keyword>, CEO, <keyword id="95879" type="COMPANY" weightage="20" keywordseo="Serum-Institute-of-India">Serum Institute of India</keyword> (SII) has said that vaccine nationalism in <keyword id="6407494" type="UNKNOWN" weightage="20" keywordseo="countries">countries</keyword>, including the US and <keyword id="3658" type="LOCATION" weightage="20" keywordseo="India">India</keyword> is likely to derail efforts to deliver 2 billion doses to poorer and middle-income nations. In an interview with a global news wire, <keyword id="25607" type="PERSON" weightage="20" keywordseo="poonawalla">Poonawalla</keyword> said countries are holding tight to their supplies and restricting access to materials needed to make more. Indian officials have also requested more vaccines than initially expected from the company, Poonawalla was quoted as saying. "We had to dedicate a lot of our capacity, which was not originally planned for India," he said. "We're trying to balance it out as much as possible, but again for the <keyword id="10943125" type="UNKNOWN" weightage="20" keywordseo="first-few-months">first few months</keyword> we have been directed to prioritise supplies to India and certain other countries that have a high disease burden." The company is responsible for providing more than half of the shots used so far in the WHO-backed Covax program that aims to provide equitable vaccine access across the world. Poonawalla said it will take two to three months for shipments to Covax to really pick up, and reaching the 2021 target of 2 billion doses will be challenging, he said, predicting it will "spill over by a few months". In an earlier tweet in February, Poonwalla had said SII has been asked to prioritise the huge needs of India and had asked "countries and governments" to be patient. "Dear countries &amp; governments, as you await #COVISHIELD supplies, I humbly request you to please be patient, @SerumInstIndia has been directed to prioritise the huge needs of India and along with that balance the needs of the rest of the world. We are trying our best," he said in the tweet. He had also assured <keyword id="6356687" type="LOCATION" weightage="20" keywordseo="canada">Canada</keyword> of vaccine delivery. "Dear Hon'ble PM @JustinTrudeau, I thank you for your warm words towards India and it's vaccine industry. As we await regulatory approvals from Canada, I assure you, @SerumInstIndia will fly out #COVISHIELD to Canada in less than a month; I'm on it!" SEE ALSO: <a href="https://www.businessinsider.in/stock-market/news/nazara-technologies-ipo-opens-today-should-you-subscribe/articleshow/81542657.cms">Nazara Technologies will be the first pure-play gaming company to debut on the Indian public markets – analysts are all in for it</a> <a href="https://www.businessinsider.in/stock-market/news/suryoday-small-finance-bank-initial-public-offer-ipo-worth-581-crore-live-should-you-subscribe/articleshow/81543610.cms">Suryoday Small Finance Bank IPO worth ₹581 crore opens today – should you subscribe?</a>

SII CEO believes 'vaccine nationalism' in India and the US could derail efforts to deliver two billion doses to poorer nations

<ul><li>Adar Poonawalla’s Serum Institute of India has bought a stake in the initial public offering (IPO) bound Policybazaar.</li><li>The investment firm True North has sold a part of its stake in PolicyBazaar to five different firms.</li><li>Policybazaar is reportedly looking to head for an IPO in 2021.</li></ul>Adar Poonawalla-headed vaccine maker Serum Institute of India (SII) has bought a minority stake in the initial public offering (IPO) bound Policybazaar. The investment firm True North (formerly India Value Fund) has sold a part of its stake in PolicyBazaar to five different firms – SII, Ashoka India Equity Investment Trust Plc, Triumph Global Holdings Pte, IIFL Special Opportunities Fund Series 8 and India Acorn Fund. The financial details of the deal weren’t disclosed. “True North has been and continues to be a good friend, advisor and has supported us as an investor through the last few years. We are grateful for that, and glad to see them having a good partial exit, we welcome on board the new shareholders. True North continues to be an investor and we thank them for the confidence,” said Yashish Dahiya, chief executive of Policybazaar in a press statement. India’s online insurance unicorn Policybazaar is <a href="https://www.ndtv.com/business/policybazaar-ipo-news-softbank-backed-policybazaar-eyes-2021-public-offer-in-indian-start-up-debut-2265523">reportedly </a>looking to head for an IPO in 2021. Backed by investors like SoftBank’s Vision Fund, Tiger Global Management and Tencent Holdings, Policybazaar was last valued at $3.5 billion. “We’ve had a great partnership with PolicyBazaar over the last three years. We are extremely pleased with the company’s sustained growth momentum and efficiency in delivering great results in spite of the challenging market conditions. We will continue to support PolicyBazaar as it heads towards public markets in the next 12-15 months and scripts many more success stories,” said Divya Sehgal, partner at True North. SII’s subsidiary Poonawalla Finance has been ramping up its presence in the Indian fintech sector. In February, it had bought a majority stake in NBFC Magma Fincorp for ₹3,450 crore. Last year, Poonawalla Finance had partnered with the startup Capital Float to disburse ₹500 crore in loans. Poonawalla Finance, which was founded in April 2019 as a part of the $9.8 billion Cyrus Poonawalla group, has had a good start. It already has over ₹1500 crore in assets under management. SEE ALSO: <a href="https://www.businessinsider.in/business/startups/news/sharechat-is-2021-9th-unicorn-as-it-raises-over-500-million-from-tiger-global-snap-and-twitter/articleshow/81964106.cms">ShareChat is this year’s 9th unicorn as it raises over $500 million from Tiger Global, Snap and Twitter</a>

You Searched For "poonawalla" and got 8 results

India’s vaccine king Adar Poonawalla will pay $69,000 a week to live on the same neighbourhood as Winston Churchill once did

BI India Bureau

The leader of one of the world's biggest vaccine manufacturers said he fled India because of menacing threats

Yelena Dzhanova

Serum Institute to roll out COVID-19 vaccine for children in six months, says CEO Adar Poonawalla

PTI

Covovax vaccine to get approval as a booster in 10-15 days: Adar Poonawalla

PTI

Cyrus Poonawalla, India’s vaccine king, multiplied his wealth nearly 5 times in a decade

Preeti Soni

COVID-19 vaccine will be priced at ₹1,000 and would be available by February for healthcare workers and elderly people, says Serum CEO Adar Poonawalla

PTI

SII CEO believes 'vaccine nationalism' in India and the US could derail efforts to deliver two billion doses to poorer nations

IANS

Serum Institute of India buys into IPO-bound insurance unicorn PolicyBazaar, as True North sells part stake in secondary sale

Sanchita Dash

Popular Keywords

Buying Guides